Vertex Acquires Crinetics for $85 Per Share in $10 Billion Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Source: NASDAQ.COM
- Acquisition Overview: Vertex Pharmaceuticals is acquiring Crinetics for $85 per share in cash, totaling approximately $10 billion, or about $8.8 billion net of cash, indicating Vertex's strong strategic intent.
- Significant Stock Reaction: Crinetics' shares surged over 99% in after-hours trading to $83.64, reflecting a positive market response to the acquisition, which may enhance Crinetics' market position.
- Product Line Expansion: The acquisition will provide Vertex with key assets like PALSONIFY (paltusotine) and Atumelnant, which are expected to generate over $5 billion in annual revenue, significantly boosting Vertex's revenue growth.
- Robust Financing Arrangement: Vertex plans to finance the acquisition through a combination of cash and debt, supported by $4.5 billion of fully committed bridge financing from Bank of America and Morgan Stanley, ensuring the transaction proceeds smoothly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.230
Low
67.00
Averages
89.40
High
105.00
Current: 42.230
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ademi LLP Investigates Crinetics for Fiduciary Breaches
- Shareholder Rights Investigation: Ademi LLP is investigating Crinetics for potential breaches of fiduciary duty in its transaction with Vertex, aiming to protect shareholder rights and ensure transparency in corporate governance.
- Transaction Value Assessment: Crinetics shareholders are set to receive $85.00 per share, totaling approximately $10 billion in equity value, with a net value of $8.8 billion after estimated cash acquired, highlighting the substantial returns but raising concerns about the board's conduct.
- Anti-competitive Clauses: The transaction agreement imposes unreasonable restrictions on competing bids, penalizing Crinetics significantly if it accepts alternative offers, which could harm shareholder interests and limit market competition, prompting legal scrutiny.
- Board Accountability Review: We are examining whether Crinetics' board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with shareholder best interests and avoiding potential conflicts of interest and misconduct.
See More
Vertex Acquires Crinetics for $10 Billion to Expand Rare Disease Portfolio
- Acquisition of Crinetics: Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, aiming to expand its business into endocrine diseases, with the potential to add up to $5 billion in annual revenue over the long term, although the market reacted negatively in the short term, pushing the stock down about 2%.
- Strategic Fit: Vertex CEO Reshma Kewalramani praised the acquisition as an excellent strategic fit, as Crinetics focuses on serious diseases in specialty markets with significant unmet needs, and it is expected to contribute revenue immediately through the ongoing launch of the Palsonify medicine.
- Revenue Growth Potential: The growing demand for therapeutics in endocrine diseases provides Vertex with a clear runway for double-digit revenue growth in the coming years, with Crinetics in the portfolio further solidifying its market position.
- Strong Market Performance: Since February 2022, Vertex's stock has outperformed the S&P 500 by 45%, demonstrating strong investor appeal, particularly in the current market environment.
See More
Analyst Target Price vs ETF Performance Analysis
- ETF Potential Analysis: The iShares US Pharmaceuticals ETF (IHE) has an implied analyst target price of $109.89 per unit, while trading at $100.19, indicating a 9.68% upside, reflecting market optimism about the ETF's future performance.
- Outstanding Stock Performance: Crinetics Pharmaceuticals (CRNX) trades at $42.03, with an analyst target price of $83.14, suggesting a potential upside of 97.82%, showcasing strong market confidence in its future growth.
- Optimistic Industry Outlook: CorMedix (CRMD) is priced at $8.79, with a target price of $14.00, indicating a 59.27% upside, reflecting analysts' positive expectations regarding its products and market demand.
- Zoetis Growth Potential: Zoetis (ZTS) trades at $75.42, with an analyst target price of $114.12, showing a 51.32% upside, indicating analysts' optimism about its continued growth in the animal health sector.
See More
Fiserv Discusses Sale of Payments Business with Major Banks
- Stock Surge: Fiserv shares rallied over 5% after The Wall Street Journal reported discussions with major banks like JPMorgan and Bank of America regarding the sale of its payments infrastructure business, potentially leading to strategic restructuring and enhanced market competitiveness.
- Acquisition Deal: Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand its product line in rare hormonal disease treatments, although Vertex shares dipped nearly 1%, this deal is expected to strengthen its market position.
- Stock Upgrade: First Solar's stock rose nearly 3% after Deutsche Bank upgraded its rating from neutral to buy, with analysts citing potential trade policy shifts as a reason for investors to buy the dip, boosting market confidence.
- EV Stock Decline: Rivian shares tumbled 9% despite revenue and delivery guidance exceeding market expectations, as the company announced a plan to sell 75 million new shares for a significant capital raise, negatively impacting investor sentiment.
See More
Crinetics Pharmaceuticals Doubles After Vertex Acquisition Deal
- Acquisition Surge: Crinetics Pharmaceuticals' shares doubled to $85 per share after Vertex Pharmaceuticals agreed to acquire the company in an all-cash deal valued at approximately $10 billion, with the transaction expected to close in Q3 2026, which will immediately boost Vertex's revenue, particularly through the launch of Palsonify for acromegaly.
- Potential Revenue Opportunities: Vertex anticipates that the combined assets will generate over $5 billion in peak annual revenue, especially with its pipeline candidate atumelnant potentially becoming a multi-billion-dollar market opportunity, highlighting the strategic significance of the acquisition.
- Divergent Market Reactions: While Crinetics' stock surged, Rivian Automotive's shares fell by 9% due to the announcement of a 75 million share Class A stock offering, overshadowing its stronger-than-expected Q2 revenue guidance, indicating investor caution towards electric vehicle manufacturers.
- Growing Industry Concerns: Micron Technology's shares dropped by 5% as investor worries about Samsung Electronics and SK Hynix's capital spending plans potentially leading to a memory supply glut intensified, further impacting the performance of the entire memory semiconductor sector.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
Ademi LLP Investigates Crinetics for Fiduciary Breaches
- Shareholder Rights Investigation: Ademi LLP is investigating Crinetics for potential breaches of fiduciary duty in its transaction with Vertex, aiming to protect shareholder rights and ensure transparency in corporate governance.
- Transaction Value Assessment: Crinetics shareholders are set to receive $85.00 per share, totaling approximately $10 billion in equity value, with a net value of $8.8 billion after estimated cash acquired, highlighting the substantial returns but raising concerns about the board's conduct.
- Anti-competitive Clauses: The transaction agreement imposes unreasonable restrictions on competing bids, penalizing Crinetics significantly if it accepts alternative offers, which could harm shareholder interests and limit market competition, prompting legal scrutiny.
- Board Accountability Review: We are examining whether Crinetics' board has fulfilled its fiduciary duties to all shareholders, ensuring that their decisions align with shareholder best interests and avoiding potential conflicts of interest and misconduct.
See More
Vertex Acquires Crinetics for $10 Billion to Expand Rare Disease Portfolio
- Acquisition of Crinetics: Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, aiming to expand its business into endocrine diseases, with the potential to add up to $5 billion in annual revenue over the long term, although the market reacted negatively in the short term, pushing the stock down about 2%.
- Strategic Fit: Vertex CEO Reshma Kewalramani praised the acquisition as an excellent strategic fit, as Crinetics focuses on serious diseases in specialty markets with significant unmet needs, and it is expected to contribute revenue immediately through the ongoing launch of the Palsonify medicine.
- Revenue Growth Potential: The growing demand for therapeutics in endocrine diseases provides Vertex with a clear runway for double-digit revenue growth in the coming years, with Crinetics in the portfolio further solidifying its market position.
- Strong Market Performance: Since February 2022, Vertex's stock has outperformed the S&P 500 by 45%, demonstrating strong investor appeal, particularly in the current market environment.
See More
Analyst Target Price vs ETF Performance Analysis
- ETF Potential Analysis: The iShares US Pharmaceuticals ETF (IHE) has an implied analyst target price of $109.89 per unit, while trading at $100.19, indicating a 9.68% upside, reflecting market optimism about the ETF's future performance.
- Outstanding Stock Performance: Crinetics Pharmaceuticals (CRNX) trades at $42.03, with an analyst target price of $83.14, suggesting a potential upside of 97.82%, showcasing strong market confidence in its future growth.
- Optimistic Industry Outlook: CorMedix (CRMD) is priced at $8.79, with a target price of $14.00, indicating a 59.27% upside, reflecting analysts' positive expectations regarding its products and market demand.
- Zoetis Growth Potential: Zoetis (ZTS) trades at $75.42, with an analyst target price of $114.12, showing a 51.32% upside, indicating analysts' optimism about its continued growth in the animal health sector.
See More
Fiserv Discusses Sale of Payments Business with Major Banks
- Stock Surge: Fiserv shares rallied over 5% after The Wall Street Journal reported discussions with major banks like JPMorgan and Bank of America regarding the sale of its payments infrastructure business, potentially leading to strategic restructuring and enhanced market competitiveness.
- Acquisition Deal: Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand its product line in rare hormonal disease treatments, although Vertex shares dipped nearly 1%, this deal is expected to strengthen its market position.
- Stock Upgrade: First Solar's stock rose nearly 3% after Deutsche Bank upgraded its rating from neutral to buy, with analysts citing potential trade policy shifts as a reason for investors to buy the dip, boosting market confidence.
- EV Stock Decline: Rivian shares tumbled 9% despite revenue and delivery guidance exceeding market expectations, as the company announced a plan to sell 75 million new shares for a significant capital raise, negatively impacting investor sentiment.
See More
Crinetics Pharmaceuticals Doubles After Vertex Acquisition Deal
- Acquisition Surge: Crinetics Pharmaceuticals' shares doubled to $85 per share after Vertex Pharmaceuticals agreed to acquire the company in an all-cash deal valued at approximately $10 billion, with the transaction expected to close in Q3 2026, which will immediately boost Vertex's revenue, particularly through the launch of Palsonify for acromegaly.
- Potential Revenue Opportunities: Vertex anticipates that the combined assets will generate over $5 billion in peak annual revenue, especially with its pipeline candidate atumelnant potentially becoming a multi-billion-dollar market opportunity, highlighting the strategic significance of the acquisition.
- Divergent Market Reactions: While Crinetics' stock surged, Rivian Automotive's shares fell by 9% due to the announcement of a 75 million share Class A stock offering, overshadowing its stronger-than-expected Q2 revenue guidance, indicating investor caution towards electric vehicle manufacturers.
- Growing Industry Concerns: Micron Technology's shares dropped by 5% as investor worries about Samsung Electronics and SK Hynix's capital spending plans potentially leading to a memory supply glut intensified, further impacting the performance of the entire memory semiconductor sector.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
